Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study.

Thea H WikenMarte L HøivikKaroline Anisdahl Lydia C T BuerDavid J WarrenNils BolstadMilada Cvancarova Småstuen Hagen Bjørn A Moum Asle Wilhelm Medhus

Published in: Crohn's & colitis 360 (2024)

Three of the four patients remained on subcutaneous vedolizumab after 18 months, a large proportion received treatment at standard dosing intervals, and disease activity remained stable. This indicates that switching from intravenous to subcutaneous vedolizumab treatment is convenient and safe.

Keyphrases

ulcerative colitis
disease activity
rheumatoid arthritis
systemic lupus erythematosus
end stage renal disease
patients with inflammatory bowel disease
ejection fraction
low dose
combination therapy
juvenile idiopathic arthritis
rheumatoid arthritis patients
peritoneal dialysis